Human papillomavirus testing with conventional Pap smear screening in three inner London community clinics

Journal of Family Planning and Reproductive Health Care

Volumn 33, Issue 3, 2007, Pages 171-176

  Herbert, Amanda ^a   Best, Jennifer M ^b   Chana, Parmjit ^a   Ktori, Elena ^a   Nowicki, Margaret ^c   Dunsmore, Hilda ^d   Culora, Giuseppe ^a   Arbyn, Marc ^e,f   Kubba, Ali A ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Lambeth Primary Care Trust   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervical intraepithelial neoplasia; Colposcopy; Cytological surveillance; Human papillomavirus testing; Low grade cytology triage

Indexed keywords

ADULT; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; FEMALE; HEALTH CENTER; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; SCREENING TEST; TREATMENT OUTCOME; UNITED KINGDOM; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGE DISTRIBUTION; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; COMMUNITY HEALTH SERVICES; DNA, VIRAL; FEMALE; HUMANS; LONDON; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; POPULATION SURVEILLANCE; PREVALENCE; URBAN POPULATION; VAGINAL SMEARS;

EID: 33947725263     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118907781005074     Document Type: Article

References (23)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
2. International Agency for Research on Cancer (IARC). Cervix Cancer Screening (IARC Handbook of Cancer Prevention, Vol. 10). Lyon, France: IARC, 2005; 59-115.
3. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127: 959-968.
4. Moss S, Gray A, Legood R, Vessey M, Patnick J, Kitchener H. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 2006; 332: 83-85.
5. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al.; ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56-61.
6. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-1392.
7. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188: 1393-1400.
8. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virological versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-293.
9. Arbyn M, Sasieni P, Meijer CJ, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006; 24(Suppl. 3): S78-S89.
10. Department of Health. Cervical Screening Programme, England: 2002-03. London, UK Department of Health, 2003.
11. NHS Cervical Screening Programme (NHSCSP). Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme (NHSCSP Publication No. 20). Sheffield, UK: NHSCSP, April 2004.
12. National Institute for Clinical Excellence (NICE). Guidance on the Use of Liquid-based Cytology for Cervical Screening (Technology Appraisal Guidance No. 5). London, UK: NICE, 2000.
13. Clavel C, Masure M, Bory JP, Putand I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616-1623.
14. Sasieni P, Stepniewska K, Altman D. Test for trend across ordered groups revisited. Stata Technical Bulletin 1996; 6: 193-196.
15. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-1876.
16. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1808-1816.
17. Howard M, Sellors J, Kaczorowski J. Optimizing the hybrid capture human papillomavirus test to detect cervical infra-epithelial neoplasia. Obstet Gynecol 2002; 100: 972-980.
18. Dalstein V, Riethmuller D, Sautiere JL, Pretet JL, Kantelip B, Schaal JP, et al. Detection of cervical precancer and cancer in a hospital population: benefits of testing for human papillomavirus. Eur J Cancer 2004; 40: 1225-1232.
19. National Statistics Online. http://www.statistics.gov.uk/cci/ nugget.asp?id=915 [Accessed 27 April 2007].
20. Herbert A. BSCC terminology for cervical cytology: two or three tiers? Why not five, seven or fourteen? Cytopathology 2004; 14: 245-251.
21. Solomon D, Nayar R. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria and Explanatory Notes (2nd edn). New York, NY: Springer Verlag, 2004.
22. Lowndes CM, Gill ON. Cervical cancer, human papillomavirus, and vaccination. BMJ 2005; 331: 915-916.
23. Fowkes FGR. Diagnostic vigilance. Lancet 1986; 1: 493-494.